IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v120y2016i6p612-620.html
   My bibliography  Save this article

Eight-year experience of using HTA in drug reimbursement: South Korea

Author

Listed:
  • Bae, Eun-Young
  • Hong, Ji-Min
  • Kwon, Hye-Young
  • Jang, Suhyun
  • Lee, Hye-Jae
  • Bae, SeungJin
  • Yang, Bong-Min

Abstract

This study describes the process and results of drug reimbursement decision-making in South Korea and evaluates its performance from the perspectives of the various stakeholders involved. Data were retrieved from the evaluation report posted on the Health Insurance Review and Assessment Service (HIRA) website. As of 2014, 253 new drugs had been submitted to the HIRA for appraisal. Of these, 175 (69.2%) were recommended in favor of listing and 78 (30.8%) were rejected. Furthermore, 68 of these drugs were deemed clinically improved relative to existing drugs. For those drugs that did not demonstrate clinical superiority (which was most of them), a simple price comparison to the existing drug was utilized as a gate toward listing.

Suggested Citation

  • Bae, Eun-Young & Hong, Ji-Min & Kwon, Hye-Young & Jang, Suhyun & Lee, Hye-Jae & Bae, SeungJin & Yang, Bong-Min, 2016. "Eight-year experience of using HTA in drug reimbursement: South Korea," Health Policy, Elsevier, vol. 120(6), pages 612-620.
    • Handle: RePEc:eee:hepoli:v:120:y:2016:i:6:p:612-620
    DOI: 10.1016/j.healthpol.2016.03.013
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851016300756
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2016.03.013?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang, 2013. "Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)," PharmacoEconomics, Springer, vol. 31(4), pages 257-267, April.
    2. Sorenson, Corinna & Drummond, Michael & Bhuiyan Kahn, Beena, 2013. "Medical technology as a key driver of rising health expenditures: disentangling the relationship," LSE Research Online Documents on Economics 48043, London School of Economics and Political Science, LSE Library.
    3. Yot Teerawattananon & Steve Russell & Miranda Mugford, 2007. "A Systematic Review of Economic Evaluation Literature in Thailand," PharmacoEconomics, Springer, vol. 25(6), pages 467-479, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Se Hee Lee & Seung-Lai Yoo & Joon Seok Bang & Jong Hyuk Lee, 2020. "Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007–2019)," IJERPH, MDPI, vol. 17(9), pages 1-8, April.
    2. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green, 2020. "Who should be given priority for public funding?," Health Policy, Elsevier, vol. 124(10), pages 1108-1114.
    3. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    4. Hye-Young Kwon & Brian Godman, 2017. "Drug Pricing in South Korea," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 447-453, August.
    5. Kyung-Bok Son, 2018. "Understanding the adoption of new drugs decided by several stakeholders in the South Korean market: a nonparametric event history analysis," Health Economics Review, Springer, vol. 8(1), pages 1-10, December.
    6. Carlos King Ho Wong & Olivia Wu & Bernard M. Y. Cheung, 2018. "Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 5-14, February.
    7. Seung-Lai Yoo & Dae-Jung Kim & Seung-Mi Lee & Won-Gu Kang & Sang-Yoon Kim & Jong Hyuk Lee & Dong-Churl Suh, 2019. "Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System," IJERPH, MDPI, vol. 16(2), pages 1-15, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Anderson, Pippa & Webb, Philip & Groves, Sam, 2017. "Prioritisation of specialist health care services; not NICE, not easy but it can be done," Health Policy, Elsevier, vol. 121(9), pages 978-985.
    2. Maurizio Bussolo & Johannes Koettl & Emily Sinnott, 2015. "Golden Aging," World Bank Publications - Books, The World Bank Group, number 22018.
    3. Júlia Varga, 2017. "Out-migration and attrition of physicians and dentists before and after EU accession (2003 and 2011): the case of Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(9), pages 1079-1093, December.
    4. Benjarin Santatiwongchai & Varit Chantarastapornchit & Thomas Wilkinson & Kittiphong Thiboonboon & Waranya Rattanavipapong & Damian G Walker & Kalipso Chalkidou & Yot Teerawattananon, 2015. "Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-15, May.
    5. Seksiri NIWATTISAIWONG, 2019. "The Us and High Health Care Spendings: A Comparative Case With OECD on the Three Prominent Factors," RAIS Journal for Social Sciences, Research Association for Interdisciplinary Studies, vol. 3(1), pages 1-11, May.
    6. Bae, Green & Bae, Eun Young & Bae, SeungJin, 2015. "Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea," Health Policy, Elsevier, vol. 119(5), pages 577-587.
    7. Fan, Victoria Y. & Savedoff, William D., 2014. "The health financing transition: A conceptual framework and empirical evidence," Social Science & Medicine, Elsevier, vol. 105(C), pages 112-121.
    8. Seung-Lai Yoo & Dae-Jung Kim & Seung-Mi Lee & Won-Gu Kang & Sang-Yoon Kim & Jong Hyuk Lee & Dong-Churl Suh, 2019. "Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System," IJERPH, MDPI, vol. 16(2), pages 1-15, January.
    9. Nicolas Martelli & Capucine Devaux & Hélène van den Brink & Judith Pineau & Patrice Prognon & Isabelle Borget, 2015. "A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-12, December.
    10. García-Cornejo, Beatriz & Pérez-Méndez, José A., 2018. "Assessing the effect of standardized cost systems on financial performance. A difference-in-differences approach for hospitals according to their technological level," Health Policy, Elsevier, vol. 122(4), pages 396-403.
    11. Green Bae & SeungJin Bae & Donghwan Lee & Juhee Han & Dong-Hoe Koo & Do Yeun Kim & Hee-Jun Kim & Sung Young Oh & Hee Yeon Lee & Jong Hwan Lee & Hye Sook Han & Hyerim Ha & Jin Hyoung Kang, 2021. "Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology," IJERPH, MDPI, vol. 18(6), pages 1-10, March.
    12. Gyeyoung Choi & Yujeong Kim & Gyeongseon Shin & SeungJin Bae, 2022. "Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea," IJERPH, MDPI, vol. 19(5), pages 1-14, February.
    13. Everistus Ibekwe & Carol Haigh & Fiona Duncan & Francis Fatoye, 2017. "Economic impact of routine opt‐out antenatal human immune deficiency virus screening: A systematic review," Journal of Clinical Nursing, John Wiley & Sons, vol. 26(23-24), pages 3832-3842, December.
    14. Nader Jahanmehr & Atieh Sadat Bigdeli & Hedayat Salari & Hussein Mokarami & Soheila KhodaKarim & Soheila Damiri, 2019. "Analyzing inappropriate magnetic resonance imaging (MRI) prescriptions and resulting economic burden on patients suffering from back pain," International Journal of Health Planning and Management, Wiley Blackwell, vol. 34(4), pages 1437-1447, October.
    15. Román Pérez Velasco & Naiyana Praditsitthikorn & Kamonthip Wichmann & Adun Mohara & Surachai Kotirum & Sripen Tantivess & Constanza Vallenas & Hande Harmanci & Yot Teerawattananon, 2012. "Systematic Review of Economic Evaluations of Preparedness Strategies and Interventions against Influenza Pandemics," PLOS ONE, Public Library of Science, vol. 7(2), pages 1-9, February.
    16. Jeewon Park & SeungJin Bae, 2020. "Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children," IJERPH, MDPI, vol. 17(12), pages 1-12, June.
    17. Alessandra Castelluccia & Pierpaolo Mincarone & Maria Rosaria Tumolo & Saverio Sabina & Riccardo Colella & Antonella Bodini & Francesco Tramacere & Maurizio Portaluri & Carlo Giacomo Leo, 2022. "Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review," IJERPH, MDPI, vol. 19(17), pages 1-21, August.
    18. Giuditta Callea & Aleksandra Torbica & Rosanna Tarricone, 2014. "Impatto del sistema di finanziamento a DRG sull?innovazione tecnologica in sanit?. Il caso italiano," MECOSAN, FrancoAngeli Editore, vol. 2014(89), pages 31-48.
    19. Jiryoun Gong & Juhee Han & Donghwan Lee & Seungjin Bae, 2020. "A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience," IJERPH, MDPI, vol. 17(24), pages 1-16, December.
    20. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2012. "The State of Health Economic Research in South Africa," PharmacoEconomics, Springer, vol. 30(10), pages 925-940, October.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:120:y:2016:i:6:p:612-620. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.